Subject Companies

 
News Articles for Subject Companies top ^
Control of Viral Load During Treatment Interruption of Antiretroviral Therapy Sustained and Ongoing for More than One Year in One Subject and Several Months in Another Additional Presentation Demonstrates Potential Mechanisms for Unprecedented HIV Reservoir Depletion by SB-728-T RICHMOND, Calif.
Sign-up for Sangamo BioSciences Announces Presentation At ICAAC of New Clinical Data Demonstrating Sustained Functional Control of Viremia in Multiple HIV-Infected Subjects Treated with SB-728-T investment picks
Air Canada and the Air Canada Pilots Association Reach New Agreement Subject to Ratification on Contract Terms for 10 Years Canada NewsWire MONTREAL , Oct.
Sign-up for Air Canada and the Air Canada Pilots Association Reach New Agreement Subject to Ratification on Contract Terms for 10 Years investment picks
Genocea Biosciences, Inc. (NASDAQ:GNCA), a clinical-stage biopharmaceutical company developing T cell-enabled vaccines and immunotherapies, today presented data from a Phase 1/2a study of GEN-003, the Company’s investigational immunotherapy against HSV-2, demonstrating that the immunotherapy elicited T cell, IgG and neutralizing antibody responses that remained significantly above baseline for 12 months after treatment.
Sign-up for Genocea HSV-2 Immunotherapeutic GEN-003 Elicits Significant, Durable T Cell Responses in Vaccinated Subjects investment picks
SANTA ROSA, Calif.
Sign-up for Ruthigen Treats First Human Subjects In Clinical Trial For RUT58-60 investment picks
http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1145602&ProfileId=051205&sourceType=1 CEDAR KNOLLS, NJ --
Sign-up for MYOS Corporation Announces Research Agreement With Human Metabolome Technologies America to Conduct Clinical Metabolomic Studies in Subjects Using Fortetropin(TM) investment picks
2014/10/7
Only 20 percent of manufacturers today rely on objective data to make decisions about process changes.
Sign-up for Ubisense Survey Finds 80 Percent of Manufacturers Rely on Subjective Data to Make Process Changes investment picks
2014/10/6
http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=11G023140-001&sourceType=1 http://www.marketwire.com/library/MwGo/2014/10/3/11G023140/ELS_NS_Logo_2C_RGB-939302954015.jpg http://www.marketwire.com/library/MwGo/2014/10/3/11G023140/Images/Managing_for_Results_Peter_Drucker_hi-res-1328617380692.jpg Leading business management thinker Peter Drucker is author of Managing for Results, which is now available in Elsevier's Legacy Collection.
Sign-up for Elsevier Adds Five New Subject Areas to Legacy eBook Collection investment picks

Premium Membership: Features and Benefits
Wide-Moat Screener for Stocks

Put a moat around your portfolio. Sniff out the most promising opportunities that can ride through any market.

Gold Medalist Screener for Funds

Narrow the available universe of 5000 funds to the top rated gold and silver. Then, sort for manager tenure, expense ratio, risk and return to create your own index-beating fund watchlist.

Thousands of Premium Analyst Reports

While many of our competitors measure a stock's worth with a computer program, Morningstar's staff of 150+ analyst sift through company fillings, financial data and a wealth of other sources to deliver an unvarnished review of any investment. In fact, twelve Morningstar analysts have been recognized by WSJ as "Best on the Street" in the US.

Premium Portfolio Monitor

Make decisions with confidence. Load your investments into our research center and automatically connect to all our proprietary tools and data points.

Mobile

Never be without critical research. Free with your active membership, take our Premium data and guidance wherever you go with Morningstar for iPad®, iPhone®, and Android apps.

Morningstar's Guarantee

We're looking out for you. If after your 14-day free trial, you find that a Morningstar Premium membership is not for you, cancel any time and we'll be happy to refund the unused portion - no questions asked.

Go Premium!
Exclusive Premium Member Benefits
Get the best thinking of 150+ disciplined
objective, experienced analysts-dedicated to
specific industries and securities.
+2,500 Analyst Reports
Wide Moat Screener for Stocks
Medalist Screener for Funds
Premium Portfolio Manager with X-Ray & Monitor
Premium eNewsletters
Morningstar Basic Benefits (All)
Sign up now - No charge for the first 14 days
Subject Companies
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Title |  Date |  Author |  Collection |  Interest |  Popularity Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Popularity |  Our Choices Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry |  Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry

Previous: Study Results  |  Next: Subordinated Debt